Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy

FEBS Letters

Volumn 588, Issue 2, 2014, Pages 288-297

  Ahmed, Mahiuddin ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer stem cell; GD2; Immunotherapy; Melanoma; Monoclonal antibody; Neuroblastoma; Sarcoma

Indexed keywords

5F11 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ANTIBODY; AURISTATIN; BLINATUMOMAB; CALICHEAMICIN; CHIMERIC MONOCLONAL ANTIBODY CH14.18; DUOCARMYCIN; GANGLIOSIDE GD2; GANGLIOSIDE GD2 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN ANTIMOUSE ANTIBODY; IMMUNOTOXIN; INTERLEUKIN 15; INTERLEUKIN 2; MAYTANSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14.G2A; MONOCLONAL ANTIBODY C.60C3; MONOCLONAL ANTIBODY HU14.18; MONOCLONAL ANTIBODY ME36.1; NANOPARTICLE; O ACETYL GD2 ANTIBODY; RICIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CONJUGATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEVER; HUMAN; HYPERTENSION; IMMUNE RESPONSE; ISOTOPE LABELING; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; URTICARIA;

BREAST CANCER STEM CELL; GD2; IMMUNOTHERAPY; MELANOMA; MONOCLONAL ANTIBODY; NEUROBLASTOMA; SARCOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; GANGLIOSIDES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROTEIN ENGINEERING;

EID: 84892369775     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.11.030     Document Type: Review

References (121)

1. S. Hakomori Role of Gangliosides in Tumor Progression L. Svennerholm, A.K. Asbury, R.A. Reisfeld, K. Sandhoff, K. Suzuki, G. Tettamanti, G. Toffano, Progress in Brain Research 1994 Elsevier Science BV 241 250
2. N.K. Cheung, U.M. Saarinen, J.E. Neely, B. Landmeier, D. Donovan, and P.F. Coccia Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells Cancer Res. 45 1985 2642 2649
3. H.R. Chang, C. Cordon-Cardo, A.N. Houghton, N.K. Cheung, and M.F. Brennan Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas Cancer 70 1992 633 638
4. S.C. Grant, L. Kostakoglu, M.G. Kris, S.D. Yeh, S.M. Larson, R.D. Finn, H.F. Oettgen, and N.V. Cheung Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial Eur. J. Nucl. Med. 23 1996 145 149
5. Y.J. Liang, Y. Ding, S.B. Levery, M. Lobaton, K. Handa, and S.I. Hakomori Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells Proc. Natl. Acad. Sci. USA 110 2013 4968 4973
6. V.L. Battula et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis J. Clin. Invest. 122 2012 2066 2078
7. M. Yanagisawa, S. Yoshimura, and R.K. Yu Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells ASN Neuro. 3 2011
8. C. Martinez, T.J. Hofmann, R. Marino, M. Dominici, and E.M. Horwitz Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs Blood 109 2007 4245 4248
9. H.J. Jin et al. GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells Cell. Mol. Life Sci. 67 2010 1845 1858
10. S. Hakomori Glycosylation defining cancer malignancy: new wine in an old bottle Proc. Natl. Acad. Sci. USA 99 2002 10231 10233
11. G.A. Lammie, N.K.V. Cheung, W. Gerald, M. Rosenblum, and C. Cordon-Cardo Ganglioside GD2 expression in the human nervous system and in neuroblastomas - an immunohistochemical study Int. J. Oncol. 3 1993 909 915
12. S. Yoshida, S. Fukumoto, H. Kawaguchi, S. Sato, R. Ueda, and K. Furukawa Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis Cancer Res. 61 2001 4244 4252
13. H. Shibuya et al. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3 Cancer Sci. 103 2012 1656 1664
14. A. Cazet et al. The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase Glycobiology 22 2012 806 816
15. Y.X. Chen, X.W. Chen, C.G. Li, L.J. Yue, H.R. Mai, and F.Q. Wen Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen Oncol. Rep. 29 2013 343 348
16. W. Aixinjueluo, K. Furukawa, Q. Zhang, K. Hamamura, N. Tokuda, S. Yoshida, R. Ueda, and K. Furukawa Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis J. Biol. Chem. 280 2005 29828 29836
17. M.A. Cheever et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin. Cancer Res. 15 2009 5323 5337
18. J. Heimburg-Molinaro, and K. Rittenhouse-Olson Development and characterization of antibodies to carbohydrate antigens Methods Mol. Biol. 534 2009 341 357
19. N.K. Cheung, and M.A. Dyer Neuroblastoma: developmental biology, cancer genomics, and immunotherapy Nat. Rev. Cancer 13 2013 397 411
20. S. Ladisch, R. Li, and E. Olson Ceramide structure predicts tumor ganglioside immunosuppressive activity Proc. Natl. Acad. Sci. USA 91 1994 1974 1978
21. F. Navid, V.M. Santana, and R.C. Barfield Anti-GD2 antibody therapy for GD2-expressing tumors Curr. Cancer Drug Targets 10 2010 200 209
22. S. Modak, and N.K. Cheung Disialoganglioside directed immunotherapy of neuroblastoma Cancer Invest. 25 2007 67 77
23. M. Saito, R.K. Yu, and N.K.V. Cheung Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell Biochem. Biophys. Res. Commun. 127 1985 1 7
24. N.K. Cheung et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma J. Clin. Oncol. 5 1987 1430 1440
25. N.K. Cheung, H. Guo, J. Hu, D.V. Tassev, and I.Y. Cheung Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo OncoImmunology 1 2012 477 486
26. N.K. Cheung, I.Y. Cheung, B.H. Kushner, I. Ostrovnaya, E. Chamberlain, K. Kramer, and S. Modak Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission J. Clin. Oncol. 30 2012 3264 3270
27. I.Y. Cheung, K. Hsu, and N.K. Cheung Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-gd2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor J. Clin. Oncol. 30 2012 426 432
28. B. Kushner, K. Kramer, S. Modak, and N.K. Cheung Anti-GD2 anitbody 3F8 plus granulocyte-macrophage colony stimulating factor (GM-CSF) for primary refractory neuroblastoma (NB) in the bone marrow (BM) Proc. Am. Soc. Clin. Oncol. 25 2007 526s
29. N.K. Cheung, I.Y. Cheung, B.H. Kushner, I. Ostrovnaya, E. Chamberlain, K. Kramer, and S. Modak Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission J. Clin. Oncol. 2012
30. B.H. Kushner, K. Kramer, S. Modak, and N.K. Cheung Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study J. Clin. Oncol. 29 2011 1168 1174
31. J. Thurin et al. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity Cancer Res. 47 1987 1229 1233
32. D. Iliopoulos et al. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides J. Natl Cancer Inst. 81 1989 440 444
33. S.L. Pichla, R. Murali, and R.M. Burnett The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside J. Struct. Biol. 119 1997 6 16
34. K. Mujoo, D.A. Cheresh, H.M. Yang, and R.A. Reisfeld Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth Cancer Res. 47 1987 1098 1104
35. K. Mujoo, T.J. Kipps, H.M. Yang, D.A. Cheresh, U. Wargalla, D.J. Sander, and R.A. Reisfeld Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18 Cancer Res. 49 1989 2857 2861
36. J.D. Frost et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group Cancer 80 1997 317 333
37. M. Ahmed, Y. Goldgur, J. Hu, H.F. Guo, and N.K. Cheung In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors PLoS ONE 8 2013 e63359
38. R.F. Irie, L.L. Sze, and R.E. Saxton Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines Proc. Natl. Acad. Sci. USA 79 1982 5666 5670
39. L.D. Cahan, R.F. Irie, R. Singh, A. Cassidenti, and J.C. Paulson Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2 Proc. Natl. Acad. Sci. USA 79 1982 7629 7633
40. R.F. Irie, and D.L. Morton Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2 Proc. Natl. Acad. Sci. USA 83 1986 8694 8698
41. S.D. Gillies, K.M. Lo, and J. Wesolowski High-level expression of chimeric antibodies using adapted cDNA variable region cassettes J. Immunol. Methods 125 1989 191 202
42. M.F. Ozkaynak et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study J. Clin. Oncol. 18 2000 4077 4085
43. A.L. Gilman et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group J. Clin. Oncol. 27 2009 85 91
44. A.L. Yu et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma N. Engl. J. Med. 363 2010 1324 1334
45. L.S. Sorkin et al. Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia Pain 149 2010 135 142
46. R. Slart, A.L. Yu, T.L. Yaksh, and L.S. Sorkin An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody Pain 69 1997 119 125
47. L.S. Sorkin, A.L. Yu, H. Junger, and C.M. Doom Antibody directed against GD(2) produces mechanical allodynia, but not thermal hyperalgesia when administered systemically or intrathecally despite its dependence on capsaicin sensitive afferents Brain Res. 930 2002 67 74
48. N.K. Cheung, H.F. Guo, G. Heller, and I.Y. Cheung Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma Clin. Cancer Res. 6 2000 2653 2660
49. J.N. Ye, and N.K. Cheung A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies Int. J. Cancer 50 1992 197 201
50. E.R. Sjoberg, A.E. Manzi, K.H. Khoo, A. Dell, and A. Varki Structural and immunological characterization of O-acetylated GD2. Evidence that GD2 is an acceptor for ganglioside O-acetyltransferase in human melanoma cells J. Biol. Chem. 267 1992 16200 16211
51. N. Alvarez-Rueda et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity PLoS One 6 2011 e25220
52. D. Cochonneau et al. Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo Cancer Lett. 333 2013 194 204
53. N.K. Cheung et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2 J. Nucl. Med. 45 2004 867 877
54. J. Hu, X. Huang, C.C. Ling, D.R. Bundle, and N.K. Cheung Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody J. Immunol. 183 2009 5748 5755
55. M.K. Tur et al. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines Int. J. Mol. Med. 8 2001 579 584
56. T. Rath et al. The immunologic functions of the neonatal Fc receptor for IgG J. Clin. Immunol. 33 Suppl 1 2013 S9 S17
57. D.H. Munn, and N.K. Cheung Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma Cancer Res. 47 1987 6600 6605
58. C.J. Honsik, G. Jung, and R.A. Reisfeld Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin Proc. Natl. Acad. Sci. USA 83 1986 7893 7897
59. B.H. Kushner, and N.K. Cheung GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma Blood 73 1989 1936 1941
60. E. Barker, B.M. Mueller, R. Handgretinger, M. Herter, A.L. Yu, and R.A. Reisfeld Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells Cancer Res. 51 1991 144 149
61. G.K. Antony, and A.Z. Dudek Interleukin 2 in cancer therapy Curr. Med. Chem. 17 2010 3297 3302
62. S.D. Gillies, E.B. Reilly, K.M. Lo, and R.A. Reisfeld Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells Proc. Natl. Acad. Sci. USA 89 1992 1428 1432
63. M.H. Ravindranath, A. Gonzales, D. Soh, K. Nishimoto, W.Y. Tam, A. Bilchik, D.L. Morton, and S. O'Day Interleukin-2 binds to ganglioside GD(1b) Biochem. Biophys. Res. Commun. 283 2001 369 373
64. J.A. Hank, J.E. Surfus, J. Gan, P. Jaeger, S.D. Gillies, R.A. Reisfeld, and P.M. Sondel Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2) Clin. Cancer Res. 2 1996 1951 1959
65. J.D. Pancook, J.C. Becker, S.D. Gillies, and R.A. Reisfeld Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2 Cancer Immunol. Immunother. 42 1996 88 92
66. K.L. Osenga et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group Clin. Cancer Res. 12 2006 1750 1759
67. S. Shusterman et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study J. Clin. Oncol. 28 2010 4969 4975
68. M.R. Albertini et al. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma Cancer Immunol. Immunother. 2012
69. L.S. Metelitsa, S.D. Gillies, M. Super, H. Shimada, C.P. Reynolds, and R.C. Seeger Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis Blood 99 2002 4166 4173
70. J.C. Steel, T.A. Waldmann, and J.C. Morris Interleukin-15 biology and its therapeutic implications in cancer Trends Pharmacol. Sci. 33 2012 35 41
71. C. Berger, M. Berger, R.C. Hackman, M. Gough, C. Elliott, M.C. Jensen, and S.R. Riddell Safety and immunologic effects of IL-15 administration in nonhuman primates Blood 114 2009 2417 2426
72. S. Dubois, H.J. Patel, M. Zhang, T.A. Waldmann, and J.R. Muller Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action J. Immunol. 180 2008 2099 2106
73. M. Epardaud et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells Cancer Res. 68 2008 2972 2983
74. T.A. Stoklasek, K.S. Schluns, and L. Lefrancois Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo J. Immunol. 177 2006 6072 6080
75. E. Mortier, A. Quemener, P. Vusio, I. Lorenzen, Y. Boublik, J. Grotzinger, A. Plet, and Y. Jacques Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins J. Biol. Chem. 281 2006 1612 1619
76. M. Vincent et al. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency Int. J. Cancer 133 2013 757 765
77. U.C. Wargalla, and R.A. Reisfeld Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells Proc. Natl. Acad. Sci. USA 86 1989 5146 5150
78. K. Mujoo, R.A. Reisfeld, L. Cheung, and M.G. Rosenblum A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2 Cancer Immunol. Immunother. 34 1991 198 204
79. P.B. Thomas, S.J. Delatte, A. Sutphin, A.E. Frankel, and E.P. Tagge Effective targeted cytotoxicity of neuroblastoma cells J. Pediatr. Surg. 37 2002 539 544
80. J.A. Flygare, T.H. Pillow, and P. Aristoff Antibody-drug conjugates for the treatment of cancer Chem. Biol. Drug Des. 81 2013 113 121
81. H.N. Lode, R.A. Reisfeld, R. Handgretinger, K.C. Nicolaou, G. Gaedicke, and W. Wrasidlo Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma Cancer Res. 58 1998 2925 2928
82. N.K. Cheung, B. Landmeier, J. Neely, A.D. Nelson, C. Abramowsky, S. Ellery, R.B. Adams, and F. Miraldi Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice J. Natl. Cancer Inst. 77 1986 739 745
83. N.K. Cheung, B.H. Kushner, S.J. Yeh, and S.M. Larson 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study Prog. Clin. Biol. Res. 385 1994 319 328
84. S.D. Yeh, S.M. Larson, L. Burch, B.H. Kushner, M. Laquaglia, R. Finn, and N.K. Cheung Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities J. Nucl. Med. 32 1991 769 776
85. S. Modak, and N.K. Cheung Antibody-based targeted radiation to pediatric tumors J. Nucl. Med. 46 Suppl 1 2005 157S 163S
86. K. Kramer et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma J. Neurooncol. 97 2010 409 418
87. K.D. Orcutt, A.L. Slusarczyk, M. Cieslewicz, B. Ruiz-Yi, K.R. Bhushan, J.V. Frangioni, and K.D. Wittrup Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging Nucl. Med. Biol. 38 2011 223 233
88. K. Cho, X. Wang, S. Nie, Z.G. Chen, and D.M. Shin Therapeutic nanoparticles for drug delivery in cancer Clin. Cancer Res. 14 2008 1310 1316
89. F. Pastorino, C. Brignole, M. Loi, D. Di Paolo, A. Di Fiore, P. Perri, G. Pagnan, and M. Ponzoni Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma Front. Oncol. 3 2013 190
90. V. Torchilin Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Deliv. Rev. 63 2011 131 135
91. T.M. Allen, and P.R. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818 1822
92. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
93. L. Raffaghello et al. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma Int. J. Cancer 104 2003 559 567
94. K.K. Matthay et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study J. Clin. Oncol. 27 2009 1007 1013
95. P. Tardi, M.B. Bally, and T.O. Harasym Clearance properties of liposomes involving conjugated proteins for targeting Adv. Drug Deliv. Rev. 32 1998 99 118
96. C. Brignole, F. Pastorino, D. Marimpietri, G. Pagnan, A. Pistorio, T.M. Allen, V. Pistoia, and M. Ponzoni Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs J. Natl. Cancer Inst. 96 2004 1171 1180
97. F. Pastorino et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models Clin. Cancer Res. 9 2003 4595 4605
98. D. Di Paolo et al. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma Mol. Ther. 19 2011 2201 2212
99. D. Di Paolo et al. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK Mol. Ther. 19 2011 1131 1140
100. F. Pastorino, C. Brignole, D. Marimpietri, P. Sapra, E.H. Moase, T.M. Allen, and M. Ponzoni Doxorubicin-loaded Fab' fragments of anti- disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice Cancer Res. 63 2003 86 92
101. J.E. Adrian, A. Wolf, A. Steinbach, J. Rossler, and R. Suss Targeted delivery to neuroblastoma of novel siRNA-anti-GD2-liposomes prepared by dual asymmetric centrifugation and sterol-based post-insertion method Pharm. Res. 28 2011 2261 2272
102. A. Tivnan et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles PLoS One 7 2012 e38129
103. M. Shen et al. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma Int. J. Nanomed. 7 2012 3319 3332
104. C.H. Wang, Y.J. Huang, C.W. Chang, W.M. Hsu, and C.A. Peng In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody Nanotechnology 20 2009 315101
105. C.-A. Peng, and C.-H. Wang Anti-neuroblastoma activity of gold nanorods bound with GD2 monoclonal antibody under near-infrared laser irradiation Cancers 3 2011 227 240
106. A.M. Scott, J.D. Wolchok, and L.J. Old Antibody therapy of cancer Nat. Rev. Cancer 12 2012 278 287
107. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 12 2012 252 264
108. R. Bargou et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 2008 974 977
109. M. Yankelevich, S.V. Kondadasula, A. Thakur, S. Buck, N.K. Cheung, and L.G. Lum Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets Pediatr. Blood Cancer 59 2012 1198 1205
110. P. Ruf et al. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model J. Transl. Med. 10 2012 219
111. N. Eissler, P. Ruf, J. Mysliwietz, H. Lindhofer, and R. Mocikat Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect Cancer Res. 72 2012 3958 3966
112. A. Krause, H.F. Guo, J.B. Latouche, C. Tan, N.K. Cheung, and M. Sadelain Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes J. Exp. Med. 188 1998 619 626
113. A.S. Lo, Q. Ma, D.L. Liu, and R.P. Junghans Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors Clin. Cancer Res. 16 2010 2769 2780
114. E. Yvon, M. Del Vecchio, B. Savoldo, V. Hoyos, A. Dutour, A. Anichini, G. Dotti, and M.K. Brenner Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells Clin. Cancer Res. 15 2009 5852 5860
115. M.A. Pule et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: presistence and antitumor activity in individuals with neuroblastoma Nature 14 2008 1264 1270
116. C.U. Louis et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma Blood 118 2011 6050 6056
117. L. Liebsch et al. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging Br. J. Cancer 109 2013 658 666
118. R. Esser et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin J. Cell Mol. Med. 16 2012 569 581
119. Y. Liu, H.W. Wu, M.A. Sheard, R. Sposto, S.S. Somanchi, L.J. Cooper, D.A. Lee, and R.C. Seeger Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy Clin. Cancer Res. 19 2013 2132 2143
120. M.S. Lawrence et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature 499 2013 214 218
121. V. Pistoia, F. Morandi, G. Bianchi, A. Pezzolo, I. Prigione, and L. Raffaghello Immunosuppressive microenvironment in neuroblastoma Front. Oncol. 3 2013 167